All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
During the EHA2021 Virtual Congress, the ALL Hub spoke with André Baruchel, Hôpital Robert-Debré, Paris, FR, about the long-term follow-up from the ZUMA-4 trial.
Phase I ZUMA-4 trial: Long-term follow-up of brexu-cel in pediatric/adolescent R/R B-ALL
In this video, Baruchel analyzes the results from the ZUMA-4 trial (NCT02625480) evaluating brexucabtagene autoleucel (KTE-X19) in pediatric and adolescent patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (R/R B-ALL). KTE-X19 is an autologous anti-CD19 chimeric antigen receptor T-cell therapy. He discusses patient characteristics, dosage, safety, efficacy, and toxicities, such as cytokine release syndrome and neurological adverse events.
Anti-CD22 CAR T-cell potency and toxicity is affected by CD4/CD8 T-cell selection
Despite recent advances made with CD19-targeted immunotherapies, there are limited effective treatment options for patients with B-cell acute lymphoblastic leukemia...
Young adult and pediatric ALL: Current induction regimens and prognostic factors
In a review published in Expert Review of Hematology, Saveria Capria and colleagues discuss the currently available induction treatments for children and adolescents...
Subscribe to get the best content related to ALL delivered to your inbox